News headlines about Tabula Rasa Healthcare (NASDAQ:TRHC) have trended positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tabula Rasa Healthcare earned a media sentiment score of 0.29 on Accern’s scale. Accern also assigned headlines about the company an impact score of 44.652472886321 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern’s scoring:
- Tabula Rasa Healthcare Inc. (TRHC) Rating Reiterated by Robert W. Baird (americanbankingnews.com)
- Tabula Rasa Healthcare to Announce Third Quarter 2017 Operating Results and Host Conference Call on Monday, November 6, 2017 (finance.yahoo.com)
- BRIEF-Tabula Rasa – files for mixed shelf offering of up to $200 mln (reuters.com)
- TABULA RASA HEALTHCARE,INC (NASDAQ:TRHC) Files An 8-K Financial Statements and Exhibits (4-traders.com)
- Tabula Rasa HealthCare (TRHC) versus Its Peers Financial Analysis (americanbankingnews.com)
Shares of Tabula Rasa Healthcare (TRHC) traded down 2.46% during midday trading on Wednesday, reaching $26.18. The company had a trading volume of 81,349 shares. The company has a 50 day moving average of $26.17 and a 200 day moving average of $26.17. Tabula Rasa Healthcare has a 12-month low of $10.39 and a 12-month high of $28.53. The firm’s market capitalization is $452.55 million.
Tabula Rasa Healthcare (NASDAQ:TRHC) last announced its earnings results on Monday, August 7th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.06. The business had revenue of $29.70 million for the quarter, compared to analysts’ expectations of $27.84 million. Tabula Rasa Healthcare had a negative return on equity of 9.58% and a negative net margin of 10.27%. Tabula Rasa Healthcare’s revenue was up 32.6% compared to the same quarter last year. Analysts anticipate that Tabula Rasa Healthcare will post $0.39 EPS for the current year.
TRHC has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Tabula Rasa Healthcare from a “hold” rating to a “strong-buy” rating and set a $31.00 target price on the stock in a research note on Wednesday, October 11th. Piper Jaffray Companies reiterated an “overweight” rating and set a $29.00 target price (up from $20.00) on shares of Tabula Rasa Healthcare in a research note on Wednesday, September 20th. Chardan Capital lifted their target price on Tabula Rasa Healthcare from $19.50 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Stifel Nicolaus reiterated a “buy” rating and set a $16.00 target price on shares of Tabula Rasa Healthcare in a research note on Friday, July 14th. Finally, ValuEngine upgraded Tabula Rasa Healthcare from a “sell” rating to a “hold” rating in a research note on Saturday, September 30th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $24.71.
In other Tabula Rasa Healthcare news, CEO Calvin H. Knowlton sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $17.21, for a total value of $137,680.00. Following the transaction, the chief executive officer now directly owns 918,362 shares of the company’s stock, valued at $15,805,010.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 45.80% of the company’s stock.
Tabula Rasa Healthcare Company Profile
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.